Corporate Profile

We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to address significant unmet medical needs in oncology.

Learn More

Minimum 15 minutes delayed. Source:

Latest News

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

2024.11.06

ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S. -based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu , PhD, MBA has been appointed

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

2024.10.31

ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

2024.10.30

-  Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S. -based, global biotech company exclusively focused on the
View All

Recent Events

View All

Investor Presentation